All In Biotech

Drug Trial Radar · NCT02794285

Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.

Last checked: Nov 20, 2026Latest source record: Jan 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 559 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

559

Actual

Start

Jun 30, 2016

Primary completion

Dec 21, 2021

Study completion Dec 21, 2021

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
PRA Health Sciences
First posted
Jun 9, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterise long-term safety and tolerability of intravenous anifrolumab.

Conditions

  • Active Systemic Lupus Erythematosus

Interventions

  • AnifrolumabBiological

    Anifrolumab IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses

  • PlaceboDrug

    Placebo IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Exposure-adjusted Incidence Rates (EAIRs) of Adverse Events of Special Interest (AESIs)Time frame: Up to a maximum of 1114 days
  2. EAIRs of Serious Adverse Events (SAEs)Time frame: Up to a maximum of 1114 days

Locations

175 sites in 24 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    El Cajon, California

  • Research Site

    Hemet, California

  • Research Site

    La Jolla, California

  • Research Site

    Los Alamitos, California

  • Research Site

    Los Angeles, California

  • Research Site

    San Leandro, California

  • Research Site

    Thousand Oaks, California

  • Research Site

    Upland, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    Bridgeport, Connecticut

  • Research Site

    Brandon, Florida

  • Research Site

    DeBary, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Ormond Beach, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Vero Beach, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Decatur, Georgia

  • Research Site

    Lawrenceville, Georgia

  • Research Site

    Marietta, Georgia

  • Research Site

    Boise, Idaho

  • Research Site

    Idaho Falls, Idaho

  • Research Site

    Cumberland, Maryland

  • Research Site

    Hagerstown, Maryland

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Nashua, New Hampshire

  • Research Site

    Freehold, New Jersey

  • Research Site

    Las Cruces, New Mexico

  • Research Site

    Brooklyn, New York

  • Research Site

    Great Neck, New York

  • Research Site

    New Hyde Park, New York

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Charlotte, North Carolina

Showing 40 of 175 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.